Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
Latest Information Update: 21 Aug 2022
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HepNet Acute HCV-V
Most Recent Events
- 26 Jun 2022 Results presented at The International Liver Congress 2022
- 02 Jul 2021 Status changed from active, no longer recruiting to completed.
- 21 Jan 2021 Planned End Date changed from 1 Apr 2021 to 1 Jun 2021.